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Abstract 
Background: Apart from baseline glycated hemoglobin (HbA1c), little is known about clinical 
parameters that affect glycemic response to a dipeptidyl peptidase-4 (DPP4) inhibitor when used 
in routine clinical practice. We aimed to use a large primary care database to assess the 
variability in response to a DPP4 inhibitor when used as add-on therapy. 
Materials and Methods: Data on 25,386 patients with type 2 diabetes, newly treated with a 
DPP4 inhibitor (2007–2013), were sourced from a United Kingdom general practice database via 
the Health Improvement Network database. Baseline clinical parameters of patients (n = 13,525) 
for whom a DPP4 inhibitor was added because of suboptimal glucose control (HbA1c >7%) 
were compared with 12-month follow-up data. An optimum response to the DPP4 inhibitor was 
defined as an HbA1c level of <7.0% at 12 months. Descriptive analyses and unadjusted 
comparisons using 2 and t tests were carried out to ascertain glycemic and body weight 
responses to treatment intensification with a DPP4 inhibitor. Predictor of response analyses were 
performed using multivariate logistic regression. 
 Results: Overall, 1,708 (13%) of our study population achieved an HbA1c level of <7%. 
Intensification with a DPP4 inhibitor was associated with significant reductions in HbA1c (–
0.5%), body weight (–0.9 kg), and total cholesterol (–0.1 mmol/L) (P < 0.001). Independent 
predictors of achieving optimal HbA1c target of <7% included the use of metformin (adjusted 
odds ratio [OR] = 2.58; 95% confidence interval [CI], 2.18–3.04) and use of metformin plus 
sulfonylurea (1.42; 95% CI, 1.21–1.68) as opposed to no use. The independent predictors of 
suboptimal glucose control included a higher baseline HbA1c level (OR = 0.64; 95% CI, 0.61–
0.68) (i.e., 1% increase in HbA1c was associated with a 36% reduced likelihood of response), 
longer diabetes duration (per every year increase) (OR = 0.85; 95% CI, 0.83–0.88), and 
intensification therapy below 9 months compared with 9–12 months. 
Conclusions: There is a significant variability in glycemic response to a DPP4 inhibitor in 
routine practice. The best effect is achieved as add-on to metformin and metformin plus 
sulfonylurea, but responses are significantly lower with increased diabetes duration and among 
patients with high HbA1c levels at baseline. 
 
Introduction 
RANDOMIZED CLINICAL TRIALS (RCTS) have examined the efficacy and safety of different 
glucose-lowering therapy (GLT) either as mono- or combination therapy in patients with type 2 
diabetes mellitus (T2D). Most patients require gradual escalation of therapy, and multiple 
treatment options are becoming more widely available, but there are few head-to-head clinical 
trials to compare outcomes in routine clinical practice using different dosing and drug 
sequencing options. In particular, the comparative effectiveness of a dipeptidyl peptidase-4 
(DPP4) inhibitor as second-, third-, or fourth-line therapy beyond metformin is unclear. 
Baseline glycated hemoglobin (HbA1c) is a well-recognized determinant of glycemic 
response to many different therapies, including DPP4 inhibitors, but beyond this little is known 
about which clinical or biochemical factors influence the glycemic response in everyday practice 
when DPP4 inhibitor is initiated as first-, second-, or third-line add-on therapy. 
The aim of the present study was to use a large United Kingdom general practice 
database to evaluate the variability and determinants of glycemic response to DPP4 inhibitor 
therapy in routine clinical practice when added to metformin (MET) or sulfonylurea (SU) 
 monotherapy and when used as add-on to dual (MET + SU) or triple (MET + SU + glitazone) 
therapy. 
 
Materials and Methods 
Study design and data source 
We conducted a retrospective cohort analysis of data from The Health Improvement 
Network database, a validated electronic database that contains anonymous patient data from 
more than 400 general practices throughout England and Wales.1 The study population 
comprised a cohort of patients identified as having T2D and registered with a general practice 
practice for >12 months before the index date. The index date (June 2007–May 2013) was 
defined as the date of initiation of DPP4 inhibitor therapy. The cohort included patients who 
were >18 years old with suboptimal glucose control (HbA1c >7.0%) 6 months or more after 
using other GLT. Patients were prescribed DPP4 inhibitor as add-on to other GLT. Standard 
computerized routines were used to identify and extract information on patient prescriptions for 
oral hypoglycemic agents using Read codes to derive the cohort of patients prescribed DPP4 
inhibitor. 
 
Treatment exposure 
Exposure was to at least two prescriptions for DPP4 inhibitor, from the index date (the 
date of the first prescription) either until there was a switch to, or addition of, another 
antidiabeties drug or the 90th day following the index date when HbA1c was recorded, or 12 
months after the index date. Patients were segregated into the following treatment groups based 
on the oral GLT they received at baseline: MET monotherapy, SU monotherapy, MET + SU as 
dual therapy, and triple therapy (MET + SU + glitazone). 
 
Outcomes 
The primary outcome was to determine the glycemic effect of intensification with DPP4 
inhibitor in terms of achieving HbA1c target of <7% after exposure to DPP4 inhibitor, as well as 
the factors that may influence this response or nonresponse according to the use of DPP4 
inhibitor as monotherapy or as add-on therapies. 
 
 Covariates 
Covariates were selected a priori on the basis of clinical significance. These are baseline 
demographic and medical parameters, referred to as "predictors of interest," and they include 
age, gender, social deprivation score (measured using the Townsend index), body weight, body 
mass index, baseline HbA1c, total cholesterol, low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, triglycerides, systolic and diastolic blood pressure, smoking status, 
duration of DPP4 inhibitor therapy, estimated duration of diabetes, use of lipid-lowering drugs, 
antihypertensive drugs, aspirin, and comorbidities (e.g., coronary heart diseases, peripheral artery 
disease, cerebrovascular disease, hypoglycemia, and heart failure). 
 
Statistical analysis 
Baseline characteristics that might distinguish between "responders" and "nonresponders" 
to DPP4 inhibitor therapy were analyzed using the 2 test for binary variables and t test for 
continuous variables. Multivariate logistic regressions were carried out to identify covariates that 
were associated with a response within 12 months. Adjusted odds ratios (ORs) for predictors and 
confounding variables were calculated and expressed as point estimates with 95% confidence 
intervals (CIs) at the significance level of 0.05. Missing data were accounted for with multiple 
imputations using the chained equation model.2 
 
Secondary analysis 
Tests for interaction were carried out to compare the metabolic effects of a DPP4 
inhibitor as add-on therapy to MET-only, SU-only, MET + SU, and MET + SU + glitazone 
regimens. Comparative analysis on changes in HbA1c levels at 12 months was carried out, and 
glycemic response end-point changes in HbA1c level were assessed based on baseline HbA1c 
categories of 7–7.5%, 7.5–8.0%, 8.0–9.0%, and ≥9%, respectively. In addition, the proportions 
of patients who achieved glycemic targets (<7.0%) were also described for the full cohort and for 
those with an HbA1c level of ≥7.5% at baseline. Sensitivity analysis was carried out to compare 
results of missing data with imputed data and to assess the reliability of the outcomes and the 
impact of missing data. All analyses were conducted using Stata software (version 13; StataCorp, 
College Station, TX).3 
 
 Bias 
We ensured “new users” of DPP4 inhibitor were used to minimize biases associated with 
prevalent use of DPP4 inhibitors.4 Post–index date exposure to any glucose-lowering therapy 
other than a DPP4 inhibitor was not permitted in our study to reduce confounding by indication.  
Patients were segregated into separate combination treatment groups to prevent confounding by 
comedication. The cohort was restricted to an estimated 12-month follow-up to reduce the risk of 
bias introduced by an overlapping treatment effect. 4 
 
Results 
Patient characteristics 
Of the 25,386 users of a DPP4 inhibitor, 13,525 patients fulfilled the criteria for cohort 
entry (Fig. 1). The cohort had a mean age of 62 years (60% male) and were predominantly obese 
(61% with a body mass index of ≥30 kg/m2) (Table 1). Treatment groups included patients 
prescribed a DPP4 inhibitor as add-on therapy to MET alone (30%), SU alone (5%), MET + SU 
(50%), and MET + SU + glitazone (15%). 
 
Response to DPP4 inhibitor therapy 
Overall, the addition of a DPP4 inhibitor resulted in a 0.5% reduction in HbA1c level (P 
< 0.001). Approximately 13% of patients achieved an HbA1c level of <7% following co-
administration of a DPP4 inhibitor, based on the criteria for response described previously. This 
response was not significantly different across gender or social deprivation index or among 
patients using antihypertensive or lipid-lowering medication. It was also not different with 
weight, body mass index, or smoking. Baseline HbA1c was significantly lower among 
responders compared with nonresponders (8.2% vs. 8.9%, respectively; P < 0.001) (Table 1). 
Co-administration of a DPP4 inhibitor was associated with a 0.9 kg reduction in body weight and 
a 0.1 mmol/L reduction in total cholesterol at 12 months (P < 0.001). 
 
Factors influencing outcomes 
After adjusting for confounders, the odds of responding to intensification with a DPP4 
inhibitor is approximately 2.6 times more when the DPP4 inhibitor is co-administered with MET 
than when it is not (adjusted OR = 2.58; 95% CI, 2.18–3.04). The odds of response is also 
 increased by 42% when DPP4 inhibitor is added to MET + SU dual therapy as opposed to none 
(OR = 1.42; 95% CI, 1.21–1.68). On the other hand, the odds of not responding to DPP4 
inhibitor independently decreased by 36% (OR = 0.64; 95% CI, 0.61–0.68) for each percentage 
unit increase in HbA1c level and also decreased by 15% (OR = 0.85; 95% CI, 0.83–0.88) for 
each unit increase in diabetes duration (years) (Table 2). 
 
Effectiveness of DPP4 inhibitor as add-on therapy 
We examined the glycemic effectiveness of DPP4 inhibitor when added to different oral 
glucose-lowering regimens. The baseline glucose-lowering medications that the patients received 
prior to intensification differed remarkably. Therefore, we did not compare effectiveness across 
treatment groups. The probability of response was predicted based on DPP4 treatment follow-up 
time in months (Fig. 2). We also assessed the probability of response according to different 
baseline HbA1c levels. In terms of absolute changes in HbA1c at 12 months, intensification with 
a DPP4 inhibitor was associated with HbA1c reduction between 0.2% and 0.6% across the 
treatment groups (Table 3). Table 3 summarizes the overall reductions in HbA1c, body weight, 
and total cholesterol across the respective treatment groups. 
Furthermore, descriptive analysis of our cohort showed the proportion of patients who 
achieved the HbA1c target of <7.0% at 1 year. Our data show that adding DPP4 inhibitor to 
monotherapy involving MET versus MET + SU resulted in 47% versus 41%, respectively, of 
users meeting the target compared with 4% of SU only users (Fig. 3). In a subgroup of patients 
with a suboptimal HbA1c level above 7.5%, our data show similar proportion of patients met a 
target below 7% when DPP4 inhibitor was added to dual MET + SU regimen and the MET-only 
regimen (45% vs. 43%, respectively) (Fig. 4). 
 
Discussion 
Overall, this large cohort study in primary care showed a significant 0.5% reduction in 
HbA1c levels at 12 months after patients with suboptimal HbA1c levels from various oral 
glucose-lowering therapies were co-administered a DPP4 inhibitor as add-on treatment. The 
addition of DPP4 inhibitor to MET was found to be the most effective in terms of glycemic 
response. Co-administering DPP4 inhibitor with MET + SU therapy was also associated with 
 responders. Conversely, a higher HbA1c level at baseline and longer diabetes duration 
independently were associated with less likelihood of achieving an HbA1c target of <7%. 
Despite the improvement in mean HbA1c following the addition of a DPP4 inhibitor to 
ongoing treatment, only 13% of patients "responded" to treatment intensification. This relatively 
low percentage of responders reflects the difficulties in achieving HbA1c target in a challenging 
cohort of patients who have failed to achieve optimal glucose levels with other oral glucose-
lowering drugs. The co-administration of a DPP4 inhibitor with MET independently predicted 
response to therapy and resulted in a significant (P < 0.001) reduction of HbA1c (–0.6%), body 
weight (–1.0 kg), and total cholesterol (0.2 mmol/L) at 12 months. Similar results were obtained 
in previous systematic reviews and meta-analysis of RCTs where treatment with sitagliptin + 
MET alone was found to be more effective at improving HbA1c levels than MET alone.5 A 
review by Chatterjee6 compared DPP4 inhibitors with MET monotherapy, as well as DPP4 
inhibitors + MET with other glucose-lowering drugs (e.g., SU, basal insulin, pioglitazone, and 
glucagon-like peptide-1 agonist). That study reported that DPP4 inhibitor monotherapy was less 
effective in reducing HbA1c levels and weight than Metformin alone. This, as well as data 
derived from our study, shows that DPP4 inhibitor are most efficacious when prescribed early in 
the course of diabetes, particularly in combination with MET. Evidence has shown that MET 
increases glucagon-like peptide-1 secretion,7 which may account for the observed synergistic 
effects of a DPP4 inhibitor with MET. 
Interestingly, despite the neutral effects of DPP4 inhibitors on body weight8 and evidence 
showing approximately 90% inhibition of plasma DPP-4 activity and an approximately threefold 
increased in active glucagon-like peptide-1 level with sitagliptin in obese patients with diabetes,9 
body mass index did not play any role in determining whether adding DPP4 inhibitor in routine 
clinical practice would result in achieving HbA1c target. 
In contrast to RCT evidence showing the efficacy of DPP4 inhibitors when used as an 
add-on therapy to SU,10,11 real-world data observed in this study suggest that concurrent use of a 
SU is a predictor of nonresponse to a DPP4 inhibitor. We have shown that with an increased 
baseline HbA1c level (>7%), DPP4 inhibitor + SU resulted in the least response and smallest 
reduction in HbA1c level compared with other regimens. We speculate that these discordant 
results may be explained by the fact that, for a given second-line glucose-lowering therapy, the 
patient population analyzed in routine clinical practice has a longer disease duration due to 
 significant delays in the addition of glycemic therapy compared with patients recruited into 
RCTs. In a previous study using the Health Improvement Network database, in patients with 
T2D, after failure of glycemic control with oral GLT, insulin initiation was delayed for at least 
1.8 years in 25% of cases and for almost 5 years in 50% of cases.12 
Studies examining the use of DPP4 inhibitor as a third- or fourth-line therapy (e.g., 
regimens involving the combination of MET, SU, and thiazolidinediones) are lacking. A recent 
study13 showed initial combination therapy with sitagliptin and pioglitazone yielded significantly 
greater reductions in HbA1c level (between 0.4 and 0.7%) than monotherapy of either drug. 
Combination therapy was found to be generally well tolerated; however, hypoglycemia and 
weight gain were reported in all treatment groups compared with the sitagliptin monotherapy 
group over the 54 weeks of the study. Our study showed that addition of a DPP4 inhibitor to the 
MET + SU + TZD regimen resulted in the least reduction of HbA1c level among patients with 
baseline HbA1c levels above 8%. Crude ORs suggest adding a DPP4 inhibitor to this triple 
therapy regimen was not associated with any significant response. This may reflect increased 
disease duration, where the use of insulin may be the most appropriate treatment choice in many 
patients. 
Our analysis was subject to some limitations inherent to observational studies; for 
example, our exposure data relate to prescriptions so we cannot be certain that glucose-lowering 
drugs were actually used. However, should there be any overestimation of exposure to the 
medications in our analysis, such a misclassification would be non-differential and only bias 
results towards unity. Potential residual confounders such as ethnicity, compliance, indications 
for different drug treatments, compliance, and differences in dosages administered to patient 
groups were not accounted for. In addition, as MET is the standard first-line medication, its use 
is much more likely to be enhanced by these residual confounders and may account for the small 
differences between first-line MET and SU users. Despite these limitations, our study highlights 
the effectiveness of DPP4 inhibitor therapy as an add-on to MET in real-world practice. We have 
shown how simple clinical and demographic parameters may influence outcomes following 
DPP4 inhibitor therapy among patients with suboptimal glucose control. 
In summary, the results of this study support the use of a DPP4 inhibitor as a second-line 
therapeutic option, especially among non-obese patients whose glucose control remains 
suboptimal despite MET treatment. In view of the potential long-term beneficial effects of DPP4 
 inhibitor on -cell function and on mass,14 as well as a previous study in a different ethnic 
group,15 this study supports the earlier use of a DPP4 inhibitor in patients with T2D. Robust 
RCTs are, however, required to fully investigate the effectiveness of DPP4 inhibitors as an add-
on to various combination therapies in patients unresponsive to various oral glucose-lowering 
drugs. 
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TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 
INHIBITOR AS ADD-ON THERAPY 
Variable 
Total (n = 
13,525) 
Responders 
(n = 1,708) 
Nonresponders 
(n = 11,817) P value 
Age (years) 62.3 (12.2) 62.9 (12.0) 62.2 (12.2) 0.04 
HbA1c (%) 8.8 (1.5) 8.2 (1.3) 8.9 (1.5) < 0.001 
SBP (mm Hg) 134.7 (15.3) 134.3 (15.0) 134.8 (15.3) 0.3 
DBP (mm Hg) 77.5 (9.6) 76.9 (9.6) 77.6 (9.6) 0.004 
TC (mmol/L) 4.3 (1.1) 4.2 (1.0) 4.3 (1.1) < 0.001 
HDL (mmol/l) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 0.2 
LDL (mmol/l) 2.2 (0.9) 2.2 (0.9) 2.3 (0.9) 0.01 
TGC (mmol/L) 2.2 (2.3) 2.1 (3.8) 2.2 (2.0) 0.2 
Weight (kg) 93.2 (21.0) 93.5 (21.3) 93.1 (21.0) 0.6 
Diabetes duration (years)a 0.8 (1.8) 0.3 (1.7) 0.9 (1.8) < 0.001 
BMI (kg/m2) 32.5 (6.5) 32.5 (6.8) 32.5 (6.5) 0.9 
 Gender     
Male 8,113 (60) 1,036 (61) 7,077 (60) — 
Female 5,412 (40) 672 (39) 4,740 (40) 0.5 
HbA1c category (%)      
7–7.5  2,306 (17) 541 (32) 1,765 (15) — 
7.5-8  2,621 (19) 454 (27) 2,167 (18) < 0.001 
8-9  4,051 (30) 445 (26) 3,606 (31) < 0.001 
≥9  4,547 (34) 268 (16) 4,279 (36) < 0.001 
BMI category (kg/m2)     
Normal (<25) 1,248 (9) 169 (10) 1,079 (9) — 
Overweight (25–29.9) 4,060 (30) 504 (30) 3,556 (30) 0.3 
Obese (≥ 0) 8,217 (61) 1,035 (61) 7,182 (61) 0.4 
Smoking status     
Nonsmoker 5,238 (39) 665 (39) 4,573 (39) — 
Current 2,053 (15) 246 (14) 1,807 (15) 0.4 
Ex-smoker 6,234 (46) 797 (47) 5,437 (46) 0.9 
Townsend Deprivation Index     
Least deprived 2,992 (22) 402 (24) 2,590 (22) — 
Less 2,875 (21) 373 (22) 2,502 (21) 0.6 
Average 2,811 (21) 355 (21) 2,456 (21) 0.3 
More 2,732 (20) 323 (19) 2,409 (20) 0.1 
Most deprived 2,115 (16) 255 (15) 1,860 (16) 0.1 
Comorbidity     
CHD 7,822 (58) 986 (58) 6,836 (58) 0.9 
PAD 2,277 (17) 255 (15) 2,022 (17) 0.02 
Cerebrovascular 3,071 (23) 402 (24) 2,669 (23) 0.4 
Heart failure 1,595 (12) 198 (12) 1,397 (12) 0.8 
Hypoglycemia 2,478 (18) 277 (16) 2,201 (19) 0.02 
Other medication     
Aspirin 5,270 (39) 705 (41) 4,565 (39) 0.04 
Antihypertensive 9,869 (73) 1,265 (74) 8,604 (73) 0.2 
LLT 10,537 (78) 1,339 (78) 9,198 (78) 0.6 
Oral antidiabetes drugs     
MET monotherapy 4,054 (30) 794 (46) 3,260 (28) < 0.001 
SU monotherapy 705 (5) 62 (4) 643 (5) 0.002 
MET + SU 6,790 (50) 703 (41) 6,087 (52) < 0.001 
MET + SU + TZD 1,76 (15) 149 (9) 1,827 (15) < 0.001 
Follow-up (months)     
9–12 8,740 (65) 1,388 (81) 7,352 (62) — 
6 to <9 1,484 (11) 96 (6) 1,388 (12) < 0.001 
3 to <6 1,627 (12) 110 (6) 1,517 (13) < 0.001 
0 to <3 1,674 (12) 114 (7) 1,560 (13) < 0.001 
Data are mean (SD) for continuous variables and frequency (percentage) for categorical 
variables. 
aEstimated as time from first glucose-lowering therapy. 
 BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; 
HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
LLT, lipid-lowering therapy; MET, metformin; PAD, peripheral arterial disease; SBP, systolic 
blood pressure; SU, sulfonylurea; TC, total cholesterol; TGC, triglyceride; TZD, 
thiazolidinedione. 
 
TABLE 2. LOGISTIC REGRESSION MODEL FOR ATTAINING <7.0% GLYCATED HEMOGLOBIN TARGET 
UPON ADDITION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR 
 
Unadjusted  Adjusted 
OR (95% CI) P value OR (95% CI) P value 
Age (years) 1.003 (1.00, 1.01) 0.3    
HbA1c (%) 0.651 (0.62, 0.69) < 0.001  0.643 (0.61, 0.68) < 0.001 
DBP (mm Hg) 0.992 (0.99, 1.00) 0.01    
TC (mmol/L) 0.971 (0.90, 1.05) 0.5    
LDL (mmol/L) 1.006 (0.92, 1.10) 0.9    
Diabetes duration (Years)a 0.850 (0.82, 0.88) < 0.001  0.852 (0.83, 0.88) < 0.001 
Comorbidity      
PAD      
No      
Yes 0.849 (0.73, 0.98) 0.8  0.876 (0.76, 1.01) 0.08 
Hypoglycemia      
No      
Yes 0.921 (0.80, 1.06) 0.3    
Other medications      
Aspirin      
No      
Yes 1.004 (0.90, 1.12) 0.9    
Oral antidiabetes drugs      
MET monotherapy      
No      
Yes 2.892 (2.39, 3.50) < 0.001  2.577 (2.19, 3.04) < 0.001 
SU monotherapy      
No      
Yes 1.347 (0.98, 1.85) 0.07    
MET + SU      
No      
Yes 1.553 (1.29, 1.87) < 0.001  1.424 (1.21, 1.68) < 0.001 
Treatment duration (months)      
9–12 1 (1.00, 1.00) —  1.00 — 
6 to <9 0.419 (0.34, 0.52) < 0.001  0.417 (0.34, 0.52) < 0.001 
3 to <6 0.470 (0.38, 0.58) < 0.001  0.466 (0.38, 0.57) < 0.001 
0 to <3 0.470 (0.38, 0.58) < 0.001  0.471 (0.38, 0.58) < 0.001 
 aEstimated as time from first glucose-lowering therapy. 
 CI, confidence interval; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; 
LDL, low-density lipoprotein; MET, metformin; OR, odds ratio of predictors of response or 
nonresponse; PAD, peripheral arterial disease; SU, sulfonylurea; TC, total cholesterol; TZD, 
Thiazolidinedione. 
 
TABLE 3. DESCRIPTIVE ANALYSIS OF GLYCATED HEMOGLOBIN, WEIGHT, AND CHOLESTEROL 
RESPONSES AFTER INTENSIFICATION WITH DIPEPTIDYL PEPTIDASE-4 INHIBITOR 
Parameter MET alone SU alone MET + SU 
MET + SU 
+ TZD 
Number of patients [n (%)] 4,054 (30) 705 (5) 6,790 (50) 1,976 (15) 
Age (years) 60 (0.2) 70 (0.5) 63 (0.1) 63 (0.3) 
HbA1c (%) 8.5 (0.02) 9.0 (0.06) 9.0 (0.02) 8.8 (0.03) 
Duration of diabetes (years)a 0.9 (0.03) 1.0 (0.07) 0.8 (0.02) 0.6 (0.04) 
Pr response 0.18 (0.01) 0.10 (0.01) 0.11 (0.01) 0.07 (0.01) 
Overall change in HbA1c (%)b –0.58 (0.02) –0.42 (0.05) –0.48 (0.02) –0.21 (0.03) 
Subgroup HbA1c change in 
HbA1c (%) 
    
7 to <7.5% –0.19 (0.04) 0.25 (0.1) 0.06 (0.04)c 0.35 (0.1) 
7.5 to <8.0% –0.32 (0.04) –0.25 (0.10) –0.16 (0.03) 0.15 (0.05) 
8.0–9.0% -0.61 (0.04) -0.23 (0.08) -0.33 (0.03) –0.14 (0.05) 
≥9.0% –1.18 (0.04) –0.88 (0.08) –0.93 (0.02) –0.77 (0.05) 
Change in weight (kg)b –1.0 (0.07) –0.20 (0.2)c –0.74 (0.05) –1.46 (0.1) 
Change in TC (mmol/L)b –0.17 (0.01) –0.06 (0.03)c –0.1 (0.01) –0.12 (0.02) 
Data are mean (SE) values unless indicated otherwise. 
aEstimated as time from first glucose-lowering therapy. 
bAbsolute change. 
c P > 0.05 for significant difference. 
HbA1c, glycated hemoglobin; MET, metformin; Pr response, predicted probability of 
response; SU, sulfonylurea; TC, total cholesterol; TZD, thiazolidinedione. 
 
FIG. 1. Study population selection flow chart. DPP4, dipeptidyl peptidase-4; DPP4i, dipeptidyl 
peptidase-4 inhibitor; GLP1-RA, glucagon-like peptide-1 receptor agonist; GLT, glucose-
lowering therapy; HbA1c, glycated hemoglobin; MET, metformin; OAD, oral antidiabetes drug; 
SGLT2i, sodium–glucose cotransporter type 2 inhibitor; SU, sulfonylurea; T2DM, type 2 
diabetes mellitus; TZD, thiazolidinedione. 
 FIG. 2. Predicted probability of response to intensification with a dipeptidyl peptidase-4 
inhibitor over time. The probability of responding to intensification with a dipeptidyl peptidase-4 
inhibitor was consistently higher when added to metformin (MET) versus sulfonylurea (SU) 
monotherapies or to MET + SU dual therapy, with the highest probability of responders after 9 
months of treatment. Response to dipeptidyl peptidase-4 inhibitor co-administration with triple 
regimen was poor. HbA1c, glycated hemoglobin; TZD, thiazolidinedione. 
FIG. 3. Proportion of patients achieving the glycated hemoglobin target level of <7.0% at 1 year. 
Among patients who achieved the glycated hemoglobin target level of <7%, the addition of 
dipeptidyl peptidase-4 inhibitor to ongoing metformin (MET) monotherapy accounted for 47% 
versus 41% for patients with ongoing MET + sulfonylurea (SU) dual therapy. TZD, 
thiazolidinedione. 
FIG. 4. Subgroup with a glycated hemoglobin level of ≥7.5% at baseline and proportion 
achieving the glycated hemoglobin target level of <7.0%. Co-administration of dipeptidyl 
peptidase-4 inhibitor with metformin (MET) + sulfonylurea (SU) dual therapy among patients 
with a glycated hemoglobin level of ≥7.5% at baseline resulted in similar proportions of patients 
meeting optimal glucose lowering as with MET monotherapy (45% vs. 43%, respectively). TZD, 
thiazolidinedione. 
